ENG/中
老虎证券
行情
交易
收费
下载
优惠与活动
帮助
TigerAI
机构
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
股权激励
关于
登录
立即注册
Toggle
美股
详情
本页面由Tiger Trade Technology Pte. Ltd.提供服务
基因编辑
409.37
+1.82
0.45%
涨家数：
3
跌家数：
1
平家数：
1
市盈率：
- -
高：
427.38
开：
410.66
低：
408.86
收：
407.55
成交量：
1,800.85万
成交额：
2.26亿
市值：
87.90亿
流通市值：
81.64亿
数据加载中...
总览
新闻资讯
BUZZ-基因编辑药物有望治疗罕见肺病和肝病，Beam Therapeutics公司股价上涨
路透中文
·
昨天
Beam Therapeutics股价盘前飙升14%，基因编辑药物在罕见肺肝疾病试验中展现积极成果
美股速递
·
昨天
Beam Therapeutics公司：60毫克剂量被确定为最佳生物剂量，单剂量队列展现优异安全性与疗效
美股速递
·
昨天
Beam Therapeutics公布BEAM-302治疗α-1抗胰蛋白酶缺乏症1/2期试验最新积极数据 支持推进关键性开发阶段
美股速递
·
昨天
Beam Therapeutics：经BEAM-302 60毫克治疗后，校正型M-AAT占总AAT的94%，同时突变型Z-AAT降低84%
美股速递
·
昨天
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK4556/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4556","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","market":"US","secType":"PLATE","nameCN":"基因编辑","latestPrice":409.37106,"timestamp":1774468799999,"preClose":407.54913,"halted":0,"volume":18008464,"delay":0,"changeRate":0.00447,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":1.82193,"latestTime":"03-25 16:00:00 EDT","open":410.65607,"high":427.38245,"low":408.8636,"amount":225709843.430229,"amplitude":0.04544,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1774512000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":2.304631,"peRate":-6.631376,"turnoverRate":0.024138,"increases":3,"decrements":1,"flats":1,"marketCap":8789733120,"floatMarketCap":8163576560},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","high":427.38245,"amplitude":0.04544,"preClose":407.54913,"low":408.8636,"pbRate":"2.304631","latestPrice":409.37106,"volume":18008464,"delay":0,"open":410.65607,"prevYearClose":431.70972,"prevWeekClose":410.1447,"prevMonthClose":496.6623,"prevQuarterClose":431.7097,"fiveDayClose":422.4592,"twentyDayClose":478.3519,"sixtyDayClose":447.8402,"secType":"PLATE","market":"US","turnoverRate":0.024138,"peRate":-6.631376,"marketCap":8789733120,"floatMarketCap":8163576560,"timestamp":1774468799999,"nameCN":"基因编辑"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4556\",,,,undefined,":{"bkCode":"BK4556","up":3,"down":1,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4556\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622798020","title":"BUZZ-基因编辑药物有望治疗罕见肺病和肝病，Beam Therapeutics公司股价上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2622798020","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622798020?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 19:28","pubTimestamp":1774438089,"startTime":"0","endTime":"0","summary":"BUZZ-基因编辑药物有望治疗罕见肺病和肝病，Beam Therapeutics公司股价上涨3月25日 - ** 生物技术公司Beam Therapeutics BEAM.O股价盘前上涨12%至27.01美元** 该公司称其实验性基因编辑药物BEAM-302在一项针对α-1抗胰蛋白酶缺乏症的早期研究中取得了令人鼓舞的结果，α-1抗胰蛋白酶缺乏症是一种可损害肺部和肝脏的罕见遗传性疾病。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL4T40D11C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861558580.USD","BK4535","BK4588","BK4139","BK4556","BEAM","LU1861559042.SGD","BK4611","BK4505","BK4585"],"gpt_icon":0},{"id":"1116095845","title":"Beam Therapeutics股价盘前飙升14%，基因编辑药物在罕见肺肝疾病试验中展现积极成果","url":"https://stock-news.laohu8.com/highlight/detail?id=1116095845","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116095845?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 19:19","pubTimestamp":1774437552,"startTime":"0","endTime":"0","summary":"Beam Therapeutics, Inc. (BEAM) 股价在盘前交易中大幅上涨14%，此前该公司宣布其研发的基因编辑药物在一项针对罕见肺肝疾病的临床试验中取得了令人鼓舞的结果。\n这一积极进展显著提振了投资者信心，推动公司股价在开盘前出现强劲上扬。试验数据的披露为Beam Therapeutics在基因治疗领域的技术实力提供了有力证明，同时也为相关罕见疾病患者带来了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","BK4585","BEAM","LU1861558580.USD","BK4588","BK4535","LU1861559042.SGD","BK4611","BK4556"],"gpt_icon":0},{"id":"1118560812","title":"Beam Therapeutics公司：60毫克剂量被确定为最佳生物剂量，单剂量队列展现优异安全性与疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1118560812","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118560812?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 19:04","pubTimestamp":1774436652,"startTime":"0","endTime":"0","summary":"Beam Therapeutics公司宣布，基于单剂量队列中展现出的卓越安全性及疗效数据，60毫克剂量已被选定为最佳生物剂量。这一决定凸显了该剂量在治疗窗口中的优势地位，为后续临床开发奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1861559042.SGD","BK4556","BEAM","BK4535","BK4505","BK4585","BK4588","BK4611","LU1861558580.USD"],"gpt_icon":0},{"id":"1125593240","title":"Beam Therapeutics公布BEAM-302治疗α-1抗胰蛋白酶缺乏症1/2期试验最新积极数据 支持推进关键性开发阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1125593240","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125593240?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 19:03","pubTimestamp":1774436620,"startTime":"0","endTime":"0","summary":"Beam Therapeutics近日公布了其在研疗法BEAM-302针对α-1抗胰蛋白酶缺乏症（AATD）的1/2期临床试验最新数据。这些积极结果有力支持该疗法向关键性临床开发阶段推进。试验数据显示，BEAM-302在安全性和有效性方面均表现出令人鼓舞的潜力，为后续研发奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4556","BK4585","BK4611","BK4535","BK4139","BK4505","LU1861559042.SGD","LU1861558580.USD","BEAM"],"gpt_icon":0},{"id":"1172694466","title":"Beam Therapeutics：经BEAM-302 60毫克治疗后，校正型M-AAT占总AAT的94%，同时突变型Z-AAT降低84%","url":"https://stock-news.laohu8.com/highlight/detail?id=1172694466","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172694466?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 19:03","pubTimestamp":1774436593,"startTime":"0","endTime":"0","summary":"在Beam Therapeutics公司BEAM-302 60毫克治疗方案下，研究数据显示校正型M-AAT占全部AAT的比例高达94%。与此同时，突变型Z-AAT水平出现显著下降，降幅达到84%。这一结果凸显了该疗法在精准编辑方面的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","BK4588","BK4585","LU1861558580.USD","BK4535","BK4139","LU1861559042.SGD","BK4611","BEAM","BK4505"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}]}}